Reaction #4136635
Related Literature (1)
openreactiondata ↗doi:10.1039/C8SC04228D
Conditions: temp:0.00; pressure:0.00; stir:
Source ID: ord-c186023793644fc99db8fe8a23d4dbe1No renderable structure data available
CC(C)NC(=O)CClChemical Intermediate
Structures, identifiers and computed properties have been matched to the database record by CAS.
| Intermediates | 2-chloro-N-propan-2-ylacetamide |
|---|---|
| IUPAC Name | — |
| CAS Number | 2895-21-8 |
| Database ID | 76171 |
| Molecular Formula | — |
| Molecular Weight | — |
Product Information
2-chloro-N-propan-2-ylacetamide (CAS 2895-21-8) product identity, structure identifiers and related reaction data for chemical intermediate research and sourcing review.
Potential Applications
For professional research and industrial use only
Database ID 76171
Safety Notice
For professional research and industrial use only. Review the supplier safety data sheet before handling.
Synthesis data
12 reactions · 12 references
Conditions: temp:0.00; pressure:0.00; stir:
Source ID: ord-c186023793644fc99db8fe8a23d4dbe1Conditions: temp:0.00; pressure:0.00; stir:
Source ID: ord-a579746b2beb4ea89755dd2d40cd73a9Conditions: temp:0.00; pressure:0.00; stir:
Source ID: ord-3bf6c649366448beac82864eab0347daConditions: temp:0.00; pressure:0.00; stir:
Source ID: ord-adb815b38e3645efaa8c5dedc0cdd12eConditions: temp:0.00; pressure:0.00; stir:
Source ID: ord-e5e19e4e54c445bb8bc519301f4db846Conditions: temp:0.00; pressure:0.00; stir:
Source ID: ord-cf068890672549c5a4e7134642166464Conditions: temp:0.00; pressure:0.00; stir:
Source ID: ord-c186023793644fc99db8fe8a23d4dbe1Conditions: temp:0.00; pressure:0.00; stir:
Source ID: ord-c186023793644fc99db8fe8a23d4dbe1Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.
Procedure: The title compound was prepared by following general procedure 7. 3,9-Dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole (100 mg, 0.46 mmol), was taken into DMF. CuI (9 mg, 0.046 mmol), L-proline (11 mg, 0.093 mmol), K3PO4 (198 mg, 0.93 mmol) were added to the solution and stirred for 10 min. at RT. 2-Chloro-N-isopropylacetamide (76 mg, 0.56 mmol) was added dropwise. The reaction mixture was heated at 90° C. for 12 h. After completion of reaction, the reaction mixture was filtered through Celite. DMF was evaporated under reduced pressure and then extracted with ethyl acetate. The organic layer was dried over Na2SO4, and concentrated under reduced pressure to obtain 7 mg of 2-(3,9-dimethyl-2,3,4,5-tetrahydroazepino[4,5-b]indol-6(1H)-yl)-N-isopropylacetamide as the TFA salt after purification by reverse-phase chromatography (C-18, 500 mm×50 mm, Mobile Phase A=0.05% TFA in water, B=0.05% TFA in acetonitrile, Gradient: 10% B to 80% B in 30 min., injection vol. 5 mL). The title compound was prepared The reaction mixture was heated at 90° C. for 12 h After completion of reaction the reaction mixture was filtered through Celite DMF was evaporated under reduced pressure extracted with ethyl acetate The organic layer was dried over Na2SO4 concentrated under reduced pressure
Source ID: ord-50eaa25e6c6042b59221c8c7aa0ce9afConditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.
Procedure: The title compound was prepared by following general procedure 7. 9-Chloro-3-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole (100 mg, 0.43 mmol), was taken into DMF. CuI (8 mg, 0.043 mmol), L-proline (9 mg, 0.086 mmol), K3PO4 (183 mg, 0.86 mmol) was added to the solution and stirred for 10 min. at RT. 2-Chloro-N-isopropylacetamide (65 mg, 0.51 mmol) was added dropwise. The reaction mixture was heated at 90° C. for 12 h. After completion of reaction, the reaction mixture was filtered through Celite. DMF was evaporated under reduced pressure and then the residue was extracted with ethyl acetate. The organic layer was dried over Na2SO4, and concentrated under reduced pressure to obtain 40 mg of 2-(9-chloro-3-methyl-2,3,4,5-tetrahydroazepino[4,5-b]indol-6(1H)-yl)-N-isopropylacetamide as the TFA salt after purification by reverse-phase chromatography (C-18, 500 mm×50 mm, Mobile Phase A=0.05% TFA in water, B=0.05% TFA in acetonitrile, Gradient: 10% B to 80% B in 30 min., injection vol. 5 mL). The title compound was prepared The reaction mixture was heated at 90° C. for 12 h After completion of reaction the reaction mixture was filtered through Celite DMF was evaporated under reduced pressure the residue was extracted with ethyl acetate The organic layer was dried over Na2SO4 concentrated under reduced pressure
Source ID: ord-412a2bb715684558af2c3d933c74b172Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.
Procedure: To a suspension of 2-(2-isopropyl-5-methyl-2H-[1,2,4]triazol-3-yl)-8-piperidin-4-yl-4,5-dihydro-6-oxa-1,3a-diaza-benzo[e]azulene hydrochloride (150 mg, 0.35 mmol) in DCM (2 mL) was added triethylamine (107 μL, 0.77 mmol). The resultant mixture was stirred for 10 minutes before the addition of 2-chloro-N-isopropyl-acetamide (52 mg, 0.38 mmol) and tetrabutylammonium iodide (13 mg, 0.04 mmol). The reaction was stirred at RT for 4 days before the reaction was washed with sodium hydrogen carbonate solution (sat. aq.). The aqueous phase was extracted with 10% MeOH in DCM (×3) and the combined organic layers dried (Na2SO4) then concentrated in vacuo. The resultant residue was purified by flash column chromatography (SiO2, gradient 0-10% MeOH in DCM) affording 277 (88 mg, 0.18 mmol, 51%). LCMS: RT=2.85 min, [M+H]+=492. 1H NMR δ (ppm) (CDCl3): 8.43 (1H, d, J=8.29 Hz), 7.59 (1H, s), 7.01 (1H, dd, J=8.34, 1.82 Hz), 6.97 (1H, s), 6.89 (1H, d, J=1.76 Hz), 5.92-5.82 (1H, m), 4.48-4.44 (2H, m), 4.42-4.38 (2H, m), 4.13-4.02 (1H, m), 3.10-2.85 (4H, m), 2.58-2.46 (1H, m), 2.38 (3H, s), 2.35-2.20 (2H, m), 1.94-1.84 (2H, s), 1.81-1.68 (2H, m), 1.54 (6H, d, J=6.64 Hz), 1.16 (6H, d, J=6.55 Hz) was washed with sodium hydrogen carbonate solution (sat. aq.) The aqueous phase was extracted with 10% MeOH in DCM (×3) the combined organic layers dried (Na2SO4) then concentrated in vacuo The resultant residue was purified by flash column chromatography (SiO2, gradient 0-10% MeOH in DCM)
Source ID: ord-af9c43fa8e7944eeaee2739cea12f428Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.
Procedure: To a suspension of 2-(2-isopropyl-5-methyl-2H-[1,2,4]triazol-3-yl)-8-piperidin-4-yl-4,5-dihydro-6-oxa-1,3a-diaza-benzo[e]azulene hydrochloride (150 mg, 0.35 mmol) in DCM (2 mL) was added triethylamine (107 μL, 0.77 mmol). The resultant mixture was stirred for 10 minutes before the addition of 2-chloro-N-isopropyl-acetamide (52 mg, 0.38 mmol) and tetrabutylammonium iodide (13 mg, 0.04 mmol). The reaction was stirred at RT for 4 days before the reaction was washed with sodium hydrogen carbonate solution (sat. aq.). The aqueous phase was extracted with 10% MeOH in DCM (×3) and the combined organic layers dried (Na2SO4) then concentrated in vacuo. The resultant residue was purified by flash column chromatography (SiO2, gradient 0-10% MeOH in DCM) affording 277 (88 mg, 0.18 mmol, 51%). LCMS: RT=2.85 min, [M+H]+=492. 1H NMR δ (ppm) (CDCl3): 8.43 (1H, d, J=8.29 Hz), 7.59 (1H, s), 7.01 (1H, dd, J=8.34, 1.82 Hz), 6.97 (1H, s), 6.89 (1H, d, J=1.76 Hz), 5.92-5.82 (1H, m), 4.48-4.44 (2H, m), 4.42-4.38 (2H, m), 4.13-4.02 (1H, m), 3.10-2.85 (4H, m), 2.58-2.46 (1H, m), 2.38 (3H, s), 2.35-2.20 (2H, m), 1.94-1.84 (2H, s), 1.81-1.68 (2H, m), 1.54 (6H, d, J=6.64 Hz), 1.16 (6H, d, J=6.55 Hz) was washed with sodium hydrogen carbonate solution (sat. aq.) The aqueous phase was extracted with 10% MeOH in DCM (×3) the combined organic layers dried (Na2SO4) then concentrated in vacuo The resultant residue was purified by flash column chromatography (SiO2, gradient 0-10% MeOH in DCM)
Source ID: ord-af9c43fa8e7944eeaee2739cea12f428PubChem References
These sources are listed in the compound's public database record.
Related Products
12 related records
CAS 32461-83-9
CAS 1046120-17-5
CAS 42275-92-3
CAS 1830-49-5
CAS 1466514-87-3
CAS 23605-23-4
CAS 63177-41-3
CAS 1211496-15-9
CAS 13916-39-7
CAS 39096-81-6
CAS 105-35-1
CAS 847805-29-2
Request a Quote
Send the required specification, quantity, destination and intended use. The CATO team will review availability and respond.
